Aethlon Medical (AEMD) investor relations material

Executive summary

• Supplement corrects scrivener's errors in the previously filed proxy card, with no changes to the body of the Proxy Statement.

• Revised proxy card is provided to ensure accurate voting instructions for the annual meeting on October 1, 2026.

Voting matters and shareholder proposals

• Shareholders will vote to elect five directors: Edward G. Broenniman, James B. Frakes, Angela Rossetti, Chetan S. Shah, M.D., and Nicolas Gikakis.

• Proposal to ratify Haskell & White LLP as independent auditor for fiscal year ending March 31, 2027.

• Advisory vote on executive compensation (say-on-pay) is included.

• Proposal to amend the 2020 Equity Incentive Plan to increase authorized shares by 100,000.

• Proposals to amend Articles of Incorporation to increase authorized common stock to 200,000,000 and authorize 20,000,000 shares of preferred stock.

• Approval sought for issuance of shares related to July 2026 public offering, future private financings, and warrant exercise inducement transactions, in compliance with Nasdaq Listing Rule 5635(d).

• Proposal to adjourn the meeting if additional proxies are needed for approval of proposals.

Board of directors and corporate governance

• Proxy solicited on behalf of the board for the annual meeting, with directors nominated for election.

• Board authorized to establish series and terms for newly authorized preferred stock.